MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1

Abstract

Previous studies have reported that miR-107 could be utilized as a potential peripheral biomarker in prostate cancer (PCa). However, the specific functions of miR-107 in prostate cancer and its relevant mechanisms are still unknown. The aim of this research was to investigate the cellular functions of miR-107 in PCa and reveal the relevant mechanisms. MicroRNA tailing quantitative real-time PCR (qRT-PCR) was adopted to measure the expression of miR-107 in PCa cell line DU145 and PC3, as well as in normal prostate cell line RWPE-1. The miR-107 expression pattern in PCa tissues and paired peritumoral tissues were determined by Chromogenic In Situ Hybridization (CISH). Cell viability, colony formation, flow cytometry cell cycle and apoptosis, wound healing and Transwell migration assays were performed to study the miR-107 functions in PCa cells. Further, qRT-PCR, western blot analysis and dual-luciferase reporter assays were conducted to verify the target of miR-107 in PCa. Results demonstrated that miR-107 was downregulated in PCa cells and tissues in comparison with normal prostate cells and peritumoral tissues, and the over-expression of miR-107 suppressed proliferation and induced G1/S arrest of PCa cells but had no effects on apoptosis or cell motility of PCa cells. MiR-107 was found to target cyclin E1 (CCNE1) in PCa cells by directly binding to its 3'-UTR. In conclusion, miR-107 could be a potential tumor suppressor in PCa, and the restoration of miR-107 might provide a new therapeutic option for PCa.

6mer Seed Toxicity in Viral microRNAs

“…Although there was no v-miRNA with the same 6mer seed as miR-34a-5p, we found a v-miRNA that shared the same 2-7 nucleotides present in the predominant 5p arm of the miR-15/16-5p miRNA family. kshv-miR-K12-6-5p (miR-K12-6-5p) contains a GC-rich trinucleotide repeat seed sequence that is found in three miRNA families with ample published evidence for having tumor suppressive activities: miR-15/16-5p (Bonci et al, 2008;Calin et al, 2002Calin et al, , 2008Han et al, 2017;Hu et al, 2018;Huang et al, 2015;Ke et al, 2013;Klein et al, 2010;Lovat et al, 2015Lovat et al, , 2018Maximov et al, 2019;Pekarsky and Croce, 2015;Rahman et al, 2014;Yang et al, 2014), miR-214-3p (Cagle et al, 2019;Fan et al, 2017;Huang et al, 2014;Liu et al, 2016;Long et al, 2015;Pang et al, 2018;Phatak et al, 2016;Wang et al, 2012;Yang et al, 2015Yang et al, , 2018bZhang et al, 2017), and miR-103/107-3p Feng et al, 2012;Fu et al, 2019;Gao et al, 2017;Piao et al, 2012;Sharma et al, 2017;Song et al, 2015;Yamakuchi et al, 2010;Yang et al, 2018a;Zhang et al, 2019) (Figure 2A). miR-K12-6-5p shares an 8mer seed sequence with miR-15a-5p, miR-15b-5p, and miR-16-5p and a 6-, 7-, or 8mer seed with other members of this family (Figure 2A).…”

<p>MicroRNA-939 Directly Targets <em>HDGF</em> to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway</p>

“…[20][21][22] Aberrant miRNA expression has been frequently identified in PCa and demonstrated to be closely associated with prostate carcinogenesis, including PCa progression. [23][24][25] In addition, miRNAs are regarded as perfect candidates for identifying tumor diagnosis and prognosis biomarkers. 26,27 Therefore, an in-depth exploration of PCa-related miRNAs may offer novel insights into the molecular pathways underlying PCa progression and facilitate the identification of novel targets for anticancer therapy.…”

The Role of miR-107 in Prostate Cancer: A Review and Experimental Evidence

“…Therefore, it has been suggested that these changes in the expression of miRNAs can be used as possible biomarkers of the disease [11]. However, the standard determination of the relative expression of miRNA requires a tissue sample from the cancer patient, which is considered a highly invasive process [12,13]. Consequently, other diagnostic methods are required that are safe, effective, and accessible.…”